Brachytherapy can be successful for high-risk prostate cases, too

Share this article:

Although brachytherapy has not been considered a highly effective form of treatment for high-risk prostate cancer, it was shown to reduce prostate cancer–specific mortality (PCSM) compared with external beam radiation therapy (EBRT) alone in a recent large analysis.

Brachytherapy, which involves the precise placement of radiation sources directly at the tumor site, is typically used to treat low- and intermediate-risk prostate cancers. Its use is less common and more controversial in high-risk cases, partially due to early retrospective studies that found this modality to be associated with lower cure rates relative to EBRT, according to a statement issued by Thomas Jefferson University (TJU) in Philadelphia, Pennsylvania. The statement described the findings of the analysis, which were published in the International Journal of Radiation Oncology, Biology, Physics, and noted that poor brachytherapy technique might have contributed to these early unfavorable results.

Timothy N. Showalter, MD, an assistant professor in the department of radiation oncology at TJU Hospital in Philadelphia, and colleagues identified 12,745 men included in the Surveillance, Epidemiology and End Results (SEER) database who had been diagnosed from 1988 through 2002 with high-grade prostate cancer of poorly differentiated grade. The men had undergone EBRT alone (73.5%), brachytherapy alone (7.1%), or EBRT plus brachytherapy (19.4%). Median follow-up for all patients was 6.4 years.

The researchers found that the use of brachytherapy or EBRT plus brachytherapy increased from 5.1% in the 1988-1992 period to 31.4% in 1998-2002. Younger age, later year of diagnosis, urban residence, and earlier T-stage of tumor were significant predictors of use of brachytherapy or EBRT plus brachytherapy.

On multivariate analysis, treatment with either brachytherapy or EBRT plus brachytherapy was associated with significant reduction in PCSM compared with EBRT alone.

“This study contradicts traditional policies of using brachytherapy in just low- and intermediate-risk patients by suggesting there may instead be an improvement in prostate cancer survival for high-risk patients,” affirmed Showalter in the TJU statement.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.